PATENT CLAIM ANALYSIS

Application Number: 16109974
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "171000"]

Abstract:
An implant comprising testosterone or an ester thereof and an aromatase inhibitor; the aromatase inhibitor may be selected from the group consisting of anastrozole, letrozole, and exemestane. In one embodiment the implant is a sustained release, subcutaneous implant. Also disclosed are therapies for patients with symptoms of relative androgen deficiency, breast cancer survivors and other therapies in which testosterone is indicated but elevated estradiol levels are avoided.

Claim (Index 13):
The method of  claim 12 , wherein the implant is a sustained release, subcutaneous implant.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 96.0
- Lexical Diversity: 1.33929
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15248556', '15520278', '16055588', '13354103', '14853130']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7818023576637354
- 35 USC 102 Novelty (BERT): 0.554483305335238
- Combined Prediction Score: 0.7590704524308857
- Mean Citation Score: 304.3221020000001
- Max Citation Score: 436.45276
- Similarity Product: 286.9926762142658

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test